Is ZBH a Buy or a Sell? The Bull and Bear Case (2026)

That depends on which case you find more convincing, and both are on this page. The bull case rests on Hips and technology are carrying the growth, not knees, with revenue (ttm) at ~$8.51B. The bear case rests on the most concrete overhang is credibility: the November 5, 2025 guidance pivot cut the price roughly 15% in a day, and in January 2026 Hagens Berman announced an investigation into whether management misled investors about international stability (as of August 2026 that remains an investigation notice, with no securities complaint on file). Analysts covering it are spread from $93.00 to $130.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. The most concrete overhang is credibility: the November 5, 2025 guidance pivot cut the price roughly 15% in a day, and in January 2026 Hagens Berman announced an investigation into whether management misled investors about international stability (as of August 2026 that remains an investigation notice, with no securities complaint on file). If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $93.00, -6.5% from the $99.48 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.

Hips and technology are carrying the growth, not knees. Hips grew ~5.1% constant currency in Q2 2026 and ~5.9% in the United States, credited to the Z1 stem and the HAMMR impaction device. The most optimistic analyst target on ZBH is $130.00, +30.7% from the $99.48 price. That figure is only reachable if this thesis works close to its best case.

The most concrete overhang is credibility: the November 5, 2025 guidance pivot cut the price roughly 15% in a day, and in January 2026 Hagens Berman announced an investigation into whether management misled investors about international stability (as of August 2026 that remains an investigation notice, with no securities complaint on file). Margin direction is the second issue, since adjusted operating margin fell ~210 basis points year over year to ~25.7% and the company itself guides to a slight full-year decline. China is small at roughly 2% of revenue and 1% of EBITDA but was down about 20% this year under volume-based procurement tenders, and VBP-style pricing pressure has a habit of spreading to other categories. Tariffs cut both ways here: a favorable ~$30M adjustment for probable US refunds helped first-half 2026 profit and does not repeat, and the company's largely domestic manufacturing base limits but does not eliminate exposure. Longer term, competitive pressure from Stryker's Mako franchise and the unresolved argument over whether GLP-1 weight-loss drugs shrink or expand the eligible joint replacement population both sit outside management's control. The most pessimistic published target is $93.00, -6.5% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.

Makes knee, hip, sports medicine and extremities implants plus the ROSA surgical robots that place them, one of the two largest orthopedic device makers.

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Hips and technology are carrying the growth, not knees) stalling in the reported numbers rather than in the narrative, the risk above (the most concrete overhang is credibility: the November 5, 2025 guidance pivot cut the price roughly 15% in a day, and in January 2026 Hagens Berman announced an investigation into whether management misled investors about international stability (as of August 2026 that remains an investigation notice, with no securities complaint on file)) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

Implants and the tools to place them. The largest lines are knee and hip replacement systems, followed by S.E.T. (sports medicine, extremities and trauma) and craniomaxillofacial and thoracic products. A separate technology and data line sells ROSA surgical robots, navigation and mixed-reality software, which mostly exists to pull implant volume rather than to earn money on its own.

Yes, and comfortably so. Q2 2026 brought net earnings of ~$198M, diluted EPS of ~$1.03 and adjusted diluted EPS of ~$2.07, with adjusted operating margin around ~25.7%. Free cash flow was ~$308M in the quarter. The debate is about growth and margin direction, not about whether the business earns money.

Growth and trust. Stryker has grown faster and taken large-joint share for several years, while Zimmer Biomet has spent that time defending its base and cut guidance abruptly on November 5, 2025, sending shares down roughly 15% in one session. At roughly ~11x forward earnings against Stryker's ~20.6x, the market is discounting the growth rate rather than the current earnings.